Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
---|
D003907 |
Dexamethasone |
[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CELF2 mRNA | affects cotreatment|increases expression | 16054899
|
D003907 |
Dexamethasone |
[Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CELF2 mRNA] | affects cotreatment|decreases reaction|increases expression | 16054899
|
D003907 |
Dexamethasone |
Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CELF2 mRNA] | affects cotreatment|decreases reaction|increases expression | 16054899
|
D015056 |
1-Methyl-3-isobutylxanthine |
[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CELF2 mRNA | affects cotreatment|increases expression | 16054899
|
D015056 |
1-Methyl-3-isobutylxanthine |
[Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CELF2 mRNA] | affects cotreatment|decreases reaction|increases expression | 16054899
|
D015056 |
1-Methyl-3-isobutylxanthine |
Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CELF2 mRNA] | affects cotreatment|decreases reaction|increases expression | 16054899
|
C089730 |
rosiglitazone |
[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CELF2 mRNA | affects cotreatment|increases expression | 16054899
|
C089730 |
rosiglitazone |
[Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CELF2 mRNA] | affects cotreatment|decreases reaction|increases expression | 16054899
|
C089730 |
rosiglitazone |
Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CELF2 mRNA] | affects cotreatment|decreases reaction|increases expression | 16054899
|
D013749 |
Tetrachlorodibenzodioxin |
Tetrachlorodibenzodioxin results in decreased expression of CELF2 mRNA | decreases expression | 16443690
|
D013749 |
Tetrachlorodibenzodioxin |
[Tetrachlorodibenzodioxin co-treated with EGF protein] inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CELF2 mRNA] | affects cotreatment|decreases reaction|increases expression | 16054899
|
D013749 |
Tetrachlorodibenzodioxin |
[Tetrachlorodibenzodioxin co-treated with EGF protein] results in decreased expression of CELF2 mRNA | affects cotreatment|decreases expression | 16054899
|
D013749 |
Tetrachlorodibenzodioxin |
Tetrachlorodibenzodioxin inhibits the reaction [[Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CELF2 mRNA] | affects cotreatment|decreases reaction|increases expression | 16054899
|
D013749 |
Tetrachlorodibenzodioxin |
Tetrachlorodibenzodioxin results in decreased expression of CELF2 mRNA | decreases expression | 16054899
|
Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
---|
MESH:D000014 |
Abnormalities, Drug-Induced |
|
Tetrachlorodibenzodioxin |
3.47 | 15322242 14514962 11752688 |
MESH:D018248 |
Adenoma, Liver Cell |
|
Tetrachlorodibenzodioxin |
4.01 | 16835633 |
MESH:D000544 |
Alzheimer Disease |
|
rosiglitazone |
2.91 | 19621015 |
MESH:D000740 |
Anemia |
|
Tetrachlorodibenzodioxin |
3.34 | 11748828 |
MESH:D001169 |
Arthritis, Experimental |
|
Dexamethasone |
3.76 | 17659584 |
MESH:D001778 |
Blood Coagulation Disorders |
|
Tetrachlorodibenzodioxin |
3.47 | 12125929 |
MESH:D001836 |
Body Weight Changes |
|
Tetrachlorodibenzodioxin |
4.51 | 15340226 |
MESH:D001848 |
Bone Diseases, Developmental |
|
Tetrachlorodibenzodioxin |
3.00 | 15746008 |
MESH:D001943 |
Breast Neoplasms |
|
Tetrachlorodibenzodioxin |
1.67 | 20435547 |
MESH:D002277 |
Carcinoma |
|
Tetrachlorodibenzodioxin |
3.12 | 16835633 |
MESH:D006332 |
Cardiomegaly |
|
Tetrachlorodibenzodioxin |
2.56 | 16120746 18850075 18670907 |
MESH:D018281 |
Cholangiocarcinoma |
|
Tetrachlorodibenzodioxin |
3.53 | 16835633 |
MESH:D002972 |
Cleft Palate |
|
Tetrachlorodibenzodioxin |
2.24 | 8697196 15340226 12621046 16354765 15668235 |
MESH:D003110 |
Colonic Neoplasms |
|
Dexamethasone |
2.54 | 15824018 |
MESH:D000013 |
Congenital Abnormalities |
|
Tetrachlorodibenzodioxin |
3.43 | 17141729 14669216 |
MESH:D019465 |
Craniofacial Abnormalities |
|
Dexamethasone |
2.70 | 17728286 |
MESH:D019465 |
Craniofacial Abnormalities |
|
Tetrachlorodibenzodioxin |
2.70 | 15322242 20055451 10048152 |
MESH:D017449 |
Dermatitis, Allergic Contact |
|
Dexamethasone |
3.96 | 12438553 |
MESH:D003920 |
Diabetes Mellitus |
|
rosiglitazone |
4.67 | 17446233 |
MESH:D003924 |
Diabetes Mellitus, Type 2 |
|
rosiglitazone |
4.75 | 12642470 |
MESH:D003924 |
Diabetes Mellitus, Type 2 |
|
Tetrachlorodibenzodioxin |
4.75 | 17107852 |
MESH:D003967 |
Diarrhea |
|
Dexamethasone |
4.20 | 7237001 |
MESH:D056486 |
Drug-Induced Liver Injury |
|
Tetrachlorodibenzodioxin |
1.62 | 20420201 |
MESH:D004362 |
Drug Toxicity |
|
Tetrachlorodibenzodioxin |
3.05 | 11462148 |
MESH:D004485 |
Eczema |
|
Dexamethasone |
4.97 | 12438553 |
MESH:D004487 |
Edema |
|
Dexamethasone |
14.18 | 19703484 |
MESH:D004487 |
Edema |
|
rosiglitazone |
14.18 | 12083418 |
MESH:D004487 |
Edema |
|
Tetrachlorodibenzodioxin |
14.18 | 11000095 12711302 |
MESH:D004489 |
Edema, Cardiac |
|
Tetrachlorodibenzodioxin |
4.62 | 16714409 15322242 18230668 |
MESH:D004715 |
Endometriosis |
|
Tetrachlorodibenzodioxin |
3.42 | 10568697 9294722 |
MESH:D005124 |
Eye Abnormalities |
|
Tetrachlorodibenzodioxin |
3.31 | 11564622 |
MESH:D005234 |
Fatty Liver |
|
rosiglitazone |
4.36 | 19196556 |
MESH:D005313 |
Fetal Death |
|
Tetrachlorodibenzodioxin |
4.02 | 11858732 |
MESH:D005355 |
Fibrosis |
|
Tetrachlorodibenzodioxin |
3.51 | 20067830 |
MESH:D006058 |
Gonadal Disorders |
|
Tetrachlorodibenzodioxin |
5.32 | 10696789 |
MESH:D006330 |
Heart Defects, Congenital |
|
Tetrachlorodibenzodioxin |
2.51 | 10048152 11294989 |
MESH:D006470 |
Hemorrhage |
|
Tetrachlorodibenzodioxin |
3.76 | 11000095 |
MESH:D006529 |
Hepatomegaly |
|
Tetrachlorodibenzodioxin |
3.45 | 12621046 16120746 15340226 |
MESH:D006548 |
Hernia, Diaphragmatic |
|
Dexamethasone |
3.18 | 7520565 |
MESH:D006869 |
Hydronephrosis |
|
Tetrachlorodibenzodioxin |
4.77 | 16959395 18606429 16354765 15340226 8697196 |
MESH:D006930 |
Hyperalgesia |
|
rosiglitazone |
4.24 | 12083418 |
MESH:D006973 |
Hypertension |
|
Dexamethasone |
5.66 | 17042910 |
MESH:D006973 |
Hypertension |
|
Tetrachlorodibenzodioxin |
5.66 | 18670907 18850075 |
MESH:D007077 |
Ileal Diseases |
|
1-Methyl-3-isobutylxanthine |
6.17 | 18306037 |
MESH:D007249 |
Inflammation |
|
Dexamethasone |
9.51 | 8960868 11099482 |
MESH:D007249 |
Inflammation |
|
rosiglitazone |
9.51 | 12083418 |
MESH:D007249 |
Inflammation |
|
Tetrachlorodibenzodioxin |
9.51 | 12878042 12200463 |
MESH:D007333 |
Insulin Resistance |
|
rosiglitazone |
4.04 | 16306350 |
MESH:D007569 |
Jaw Abnormalities |
|
Tetrachlorodibenzodioxin |
3.76 | 16580747 |
MESH:D007579 |
Jejunal Diseases |
|
1-Methyl-3-isobutylxanthine |
6.17 | 18306037 |
MESH:D008106 |
Liver Cirrhosis, Experimental |
|
Dexamethasone |
3.81 | 16718785 |
MESH:D008106 |
Liver Cirrhosis, Experimental |
|
rosiglitazone |
3.81 | 17347453 15980055 |
MESH:D008106 |
Liver Cirrhosis, Experimental |
|
Tetrachlorodibenzodioxin |
3.81 | 12878042 |
MESH:D008113 |
Liver Neoplasms |
|
Tetrachlorodibenzodioxin |
1.83 | 16984957 |
MESH:D008114 |
Liver Neoplasms, Experimental |
|
Tetrachlorodibenzodioxin |
2.33 | 12151625 |
MESH:D008175 |
Lung Neoplasms |
|
Dexamethasone |
2.53 | 15824018 11195469 |
MESH:D008175 |
Lung Neoplasms |
|
Tetrachlorodibenzodioxin |
2.53 | 11884234 19555203 |
MESH:D008325 |
Mammary Neoplasms, Experimental |
|
rosiglitazone |
3.63 | 16827153 |
MESH:D024821 |
Metabolic Syndrome X |
|
rosiglitazone |
4.72 | 17261469 |
MESH:D009101 |
Multiple Myeloma |
|
Dexamethasone |
3.78 | 15867202 16118317 15744524 |
MESH:D009190 |
Myelodysplastic Syndromes |
|
Dexamethasone |
3.74 | 9809623 |
MESH:D017202 |
Myocardial Ischemia |
|
Tetrachlorodibenzodioxin |
3.34 | 12213967 |
MESH:D009421 |
Nervous System Malformations |
|
Tetrachlorodibenzodioxin |
3.72 | 14600291 |
MESH:D010382 |
Peliosis Hepatis |
|
Tetrachlorodibenzodioxin |
4.97 | 12520081 |
MESH:D017119 |
Porphyria Cutanea Tarda |
|
Tetrachlorodibenzodioxin |
4.07 | 18163543 |
MESH:D054198 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
|
Dexamethasone |
3.74 | 21297632 |
MESH:D011297 |
Prenatal Exposure Delayed Effects |
|
Tetrachlorodibenzodioxin |
3.82 | 11118676 11896295 11399792 11222880 |
MESH:D012128 |
Respiratory Distress Syndrome, Adult |
|
Dexamethasone |
4.48 | 18379247 11700416 |
MESH:D015619 |
Respiratory System Abnormalities |
|
Tetrachlorodibenzodioxin |
4.35 | 18990726 |
MESH:D012878 |
Skin Neoplasms |
|
Tetrachlorodibenzodioxin |
2.20 | 16192470 |
MESH:D013272 |
Stomach Diseases |
|
Dexamethasone |
4.95 | 15472012 |
MESH:D013276 |
Stomach Ulcer |
|
Dexamethasone |
3.91 | 15138204 |
MESH:D013959 |
Thyroid Diseases |
|
Tetrachlorodibenzodioxin |
4.62 | 12697716 |
MESH:D014605 |
Uveitis |
|
Dexamethasone |
5.54 | 1336536 |
MESH:D054079 |
Vascular Malformations |
|
Tetrachlorodibenzodioxin |
5.32 | 12125929 |
MESH:D019282 |
Wasting Syndrome |
|
Tetrachlorodibenzodioxin |
4.97 | 15886252 |